Drug Profile
ImmunoVEX HSV2
Alternative Names: Genital herpes vaccine - Amgen; Herpes simplex virus vaccine - AmgenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioVex
- Developer Amgen
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Herpes genitalis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes genitalis (Prevention) in United Kingdom (Parenteral)
- 04 Mar 2011 BioVex has been acquired by Amgen
- 05 Mar 2010 Phase-I clinical trials in Herpes genitalis (prevention) in United Kingdom (Parenteral)